In-Vitro Evaluation of Apoptosis, Inflammation, Angiogenesis, and Neuroprotection Gene Expression in RPE Cell Treated with IFN alfa-2b
Hossein Bahari1 *, Mehrdad Afarid 1 , Fatemeh Sanie-Jahromi 1
- Poostchi Ophthalmology Research Center, Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract: DR is a microvascular disorder
most common cause VL in working middle-aged
Hyperglycemia:
1.Disruption of retinal blood vessels
2.Damage neural retina
These 2 triggers inflammatory response…
Angiogenesis , neurodegeneration, and inflammation critical feature of DR & lead RPE/photoreceptor dysfunction
Methods: Applied IFNα-2b in 2 doses (500 &1000 IU) and 2 periods of time (24 & 48hrs)
RPE cells in concentration of 10^6 cells/ml and treated IFNα-2b.
Total RNA from treated vs control RPE, RNeasy kit.
cDNA Synthesis Kit applied.
The reactions were run in Real-Time PCR.
Results: BCL-2 significantly increase in 1000IU,48hr but not significant changed in other.
BAX gene significantly increase in 1000IU,48hr No significant alteration in any other.
BCL-2/BAX ratio; apoptosis index; no significant from 1:1
in-vitro safety of IFN α-2b.
BDNF
significantly increased in1000IU,48hr
No significant alteration in any other.
VEGF
significant down-regulation in 500IU,24hr
not significantly changed in any other.
IL-1b
significantly upregulated in 1000IU,48hr
not significantly changed in any other.
Conclusion: 1. IFN α-2b is a safe drug for the treatment of RPE.
2. Lower doses and short duration may have anti-angiogenic effects.
3. higher doses with longer duration neuroprotective and inflammatory effects.
4. Anti-angiogenesis for short-time, and increasing duration may exacerbate inflammation , esp in advanced inflammation.
5. So considered situation to achieve success!
